Pulmonary Fibrosis News Forums › Forums › Treatments and Science › Clinical Trials › Ofev Phase 3 Study for Pulmonary Fibrosis Patients

  • Clinical Trials

    Ofev Phase 3 Study for Pulmonary Fibrosis Patients

    Posted by Mark Koziol on October 2, 2019 at 8:00 pm

    In today’s Pulmonary Fibrosis News, Joana Carvalo, MSC has published a news article titled; Ofev Reduces Lung Function Decline in Patients with Fibrotic Lung Diseases, Phase 3 Trial Shows. This is exciting news for patients suffering with “progressive fibrosing interstitial lung diseases”.  Ofev is currently only used to treat patients with idiopathic pulmonary fibrosis (IPF). Ofev is one of two medicines that may stop the progression of IPF. “Findings from the INBUILD study showed that the study met its primary endpoint, with Ofev reducing patients’ lung function decline by 57% over the course of one year compared with the placebo.”

    I am interested to hear forum members’ comment on what their decision will be if they are offered the opportunity to take this medicine.

    replied 4 years, 6 months ago 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.

Start of Discussion
0 of 0 replies June 2018
Now

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .